Ocugen, Inc. signed a binding term sheet for the licensing of its OCU400 modifier gene therapy for retinitis pigmentosa within the Middle East and North Africa region. Ocugen, Inc. is a biotechnology company focused on developing and commercializing gene therapies for ocular diseases.
